Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
Liquid biopsy is emerging as an essential tool in tumor monitoring and a potential
alternative and supplement to tissue biopsy for tumor genotyping, especially in relapsed or
metastatic diseases. Liquid biopsy methods for detecting T790M in ctDNA can be qualitative or
quantitative, including amplification refractory mutation system PCR (ARMS-PCR), digital
droplet polymerase chain reaction (ddPCR), and next generation sequencing (NGS)-based
methods. Comparison of multiple detecting platform for EGFR mutations in plasma samples has
been undertaken in studies to determine the most feasible assay in clinical practice. In this
study, we will investigate the usefulness of ddPCR for quantitative detection of EGFR T790M
mutation in peripheral blood, and compared the utility of ddPCR and NGS for guiding decisions
regarding osimertinib therapy in NSCLC patients who had develop resistance to first- or
second generation EGFR-TKIs.